Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Slides:

Advertisements

Similar presentations

Diet Study for Nonalcoholic Fatty Liver Disease Lab meeting.

Advertisements

Figure 1 Proposed risk stratification for patients with NAFLD

Figure 6 Cholesterol metabolism in obesity-related glomerulopathy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 148, Issue 4, Pages (April 2015)

Figure 5 Dendritic cells in liver inflammation

Figure 1 Contribution of the gut microbiota

Figure 4 Activation of clopidogrel via cytochrome P450

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Pathophysiological aspects of insulin

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 ER stress and hepatic steatosis: a vicious cycle

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 1 HCV life cycle and site of action of DAAs

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Nat. Rev. Endocrinol. doi: /nrendo

Sugar, Sugar Not So Sweet for the Liver

Figure 3 Lipid droplet formation and expansion

Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Figure 1 Regulation of hepatic glucose metabolism by the gut, brain and liver Figure 1 | Regulation of hepatic glucose metabolism by the gut, brain and.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Systems biological model of IBS

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

Figure 2 Lipid metabolism and metabolism-disrupting chemicals.

Figure 1 The major pathways of lipid metabolism

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 134, Issue 2, Pages (February 2008)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Intracellular distribution and

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Assembly and secretion of apoB100- containing lipoproteins

Schematic representation of dyslipidaemia of metabolic syndrome.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Plasma lipid exchange. Plasma lipid exchange. In the presence of increased concentrations of VLDL in the circulation, cholesteryl ester transfer protein.

Presentation transcript:

Figure 6 Possible therapeutic targets to decrease hepatic steatosis Figure 6 | Possible therapeutic targets to decrease hepatic steatosis. Interventions designed to decrease triglyceride (TG) synthesis, increase lipolysis, increase fatty acid (FA) oxidation, or increase very-low-density lipoprotein (VLDL) secretion could decrease hepatic TG content. ER, endoplasmic reticulum. Gluchowski, N. L. et al. (2017) Lipid droplets and liver disease: from basic biology to clinical implications Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.32